









Markets
/
Stocks
/
nasdaq-axsm
/

Axsome Therapeutics Inc

AXSM

182.550USD

+1.710+0.95%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

9.18BMarket Cap

LossP/E TTM



Axsome Therapeutics Inc

182.550

+1.710+0.95%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Axsome Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Axsome Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 213.05.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Axsome Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

40 / 159

Overall Ranking

115 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Axsome Therapeutics Inc Highlights

StrengthsRisks

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 670.81% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 385.69M.

Undervalued

The company’s latest PE is -39.08, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.50M shares, increasing 0.21% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 7.37K shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

213.053

Target Price

+17.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Axsome Therapeutics Inc is 8.34, ranking 73 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 170.99M, representing a year-over-year increase of 63.22%, while its net profit experienced a year-over-year increase of 26.89%.

Score

Industry at a Glance

Previous score

8.34

Change



Financials

7.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Axsome Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Axsome Therapeutics Inc is 7.11, ranking 98 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -39.08, which is -73.94% below the recent high of -10.19 and -3.59% above the recent low of -40.49.

Score

Industry at a Glance

Previous score

7.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Axsome Therapeutics Inc is 8.60, ranking 23 out of 159 in the Pharmaceuticals industry. The average price target is 185.00, with a high of 205.00 and a low of 148.00.

Score

Industry at a Glance

Previous score

8.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

213.053

Target Price

+17.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Axsome Therapeutics Inc

AXSM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Axsome Therapeutics Inc is 7.37, ranking 62 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 193.20 and the support level at 170.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.40

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-2.826

Neutral

RSI(14)

57.014

Neutral

STOCH(KDJ)(9,3,3)

33.211

Sell

ATR(14)

5.691

Low Volatility

CCI(14)

-152.927

Sell

Williams %R

54.242

Neutral

TRIX(12,20)

0.546

Sell

StochRSI(14)

18.988

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

184.432

Sell

MA10

184.938

Sell

MA20

182.244

Buy

MA50

165.412

Buy

MA100

147.318

Buy

MA200

128.358

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Axsome Therapeutics Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.28%, representing a quarter-over-quarter decrease of 2.16%. The largest institutional shareholder is The Vanguard, holding a total of 4.16M shares, representing 8.24% of shares outstanding, with 4.91% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Antecip Capital, L.L.C.

7.34M

The Vanguard Group, Inc.

Star Investors

4.17M

+5.97%

BlackRock Institutional Trust Company, N.A.

3.10M

-1.23%

Wellington Management Company, LLP

1.33M

+84.07%

RTW Investments L.P.

1.12M

-26.24%

Nomura Investment Management Business Trust

1.08M

-4.68%

Geode Capital Management, L.L.C.

997.70K

+0.83%

T. Rowe Price Associates, Inc.

Star Investors

994.50K

+72.68%

Invesco Advisers, Inc.

949.36K

+79.62%

State Street Investment Management (US)

942.96K

-1.62%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Axsome Therapeutics Inc is 7.20, ranking 42 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Axsome Therapeutics Inc’s latest ESG disclosure is at an average level in the Pharmaceuticals industry, showing no material impact on overall risk.